Compare Amgen, Inc. (AMGN) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Prospect Capital Corporation — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Prospect Capital Corporation trades at $2.26 (market cap $1.13B). The key difference: Amgen, Inc. is far larger — about 173.6× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (22.17%). Which is the better fit depends on your goals.
| AMGN | PSEC | |
|---|---|---|
Market Cap | $196.12B | $1.13B |
Sector | Health | Financials |
52-Week High | $388.16 | $3.47 |
52-Week Low | $271.18 | $2.15 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | 22.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
PSEC trades at $2.26, up 2.26% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.38 and has beaten EPS estimates for three consecutive quarters. Recent news includes a new investment in ShipOffers and the sale of Valley Electric generating $328 million. Dividend payments continue at $0.04-$0.05 monthly, supporting income appeal despite negative revenue and net income in 2025.
Outlook remains cautious due to persistent negative profitability and revenue volatility, though deep discount to NAV and high yield may attract income investors. Key risks include declining NAV, portfolio quality concerns, and analyst skepticism. Upside depends on stabilization of investment income and successful execution of senior lending strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
